好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Assessment of Retinal Structures in Patients with Relapsing-Remitting Multiple Sclerosis on Fingolimod (Gilenya®)
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-022
To examine the longitudinal effect of Fingolimod (Gilenya®) on retinal layers of patients with relapsing-remitting multiple sclerosis (RRMS).
RRMS is known to cause thinning of retinal layers over time. Retinal thinning in RRMS is found to be greater than that in normal aging. Optical coherence tomography (OCT) allows visualization and quantification of retinal layer thickness.
A single-center, prospective study was conducted in 47 patients with RRMS. All patients taking 0.5mg Fingolimod PO daily underwent OCT imaging at baseline, year 1, and year 2, which included peripapillary retinal nerve fiber layer (pRNFL) thickness and volumetric macular scans. Fully automated intra-retinal segmentation was performed to measure the thickness of the RNFL, ganglion cell (GCL), inner plexiform (IPL), outer plexiform (OPL), and outer nuclear (ONL) layers within the macula. GCL and IPL were combined to form ganglion cell – inner plexiform layers (GCIPL). Mean difference was calculated across different time points. Multivariate analysis was performed to examine the longitudinal variations on the retinal layers thickness.

TMV did not show any significant changes over a twenty-four month period (p=0.949). Macular RNFL did not show a thinning trend (p=0.904).  Global pRNFL and GCIPL showed a longitudinal thinning trend, but did not reach statistical significance (p=0.952 and p=0.917, respectively). 

 

GCIPL may be a potential more sensitive biomarker than RNFL and TMV to monitor MS progression. Fingolimod may have a neuroprotective effect on the retinal structures that might be more prominent on MV and macular RNFL. Future studies with larger samples to validate these results and to investigate the correlation between OCT findings and patient’s functional status over time are needed.
Authors/Disclosures
Jia Lin, MD (UT Health Houston, McGovern Medical School, Department of Neurology)
PRESENTER 		The institution of Dr. Lin has received research support from PPD/Contineum.
Kalyan Yarraguntla, MD (University Health Center) Dr. Yarraguntla has nothing to disclose.
Samuel Lichtman-Mikol, BA (Wayne State University) Mr. Lichtman-Mikol has nothing to disclose.
No disclosure on file
Fen Bao Fen Bao has nothing to disclose.
Carla E. Santiago-Martinez (Wayne State University) Ms. Santiago-Martinez has nothing to disclose.
Navid Seraji-Bozorgzad, MD (University of Michigan Medicine-Neurology) No disclosure on file
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine) Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.